Thymosin alpha-1: what the evidence supports, and what 2026 changed

TL;DR

• Approved abroad, not in the US - marketed as Zadaxin in more than 35 countries, principally for chronic hepatitis B; investigational in the United States.
• The best controlled evidence is negative - the TESTS phase 3 (BMJ 2025, 1,106 adults, 22 centres) found 28-day mortality of 23.4% versus 24.1% on placebo, HR 0.99, P=0.93.
• The hepatitis B case is real but dated - a 1998 RCT in 98 patients showed 40.6% complete virological response versus 9.4% in untreated controls, against a standard of care since replaced.
• The mechanism is immunological - Toll-like receptor signalling on dendritic cells with downstream effects on T-cell maturation; modulatory rather than immune-boosting.
• Not the same molecule as TB-500 - thymosin beta-4 is a distinct actin-sequestering repair protein, and evidence about one carries no weight for the other.
• Nothing in 2026 moved thymosin alpha-1 - TB-500 came off Category 2 in April and went to PCAC in July; thymosin alpha-1 was on neither list.

Educational content, not medical advice. Thymosin alpha-1 is not FDA-approved in the United States and is investigational in that setting. No doses, protocols or sourcing information appear anywhere on this page. Nothing here is a recommendation to seek, purchase or use any compound.

---

Most peptides that reach a consumer audience arrive with thin evidence and loud claims. Thymosin alpha-1 arrives the other way around. It has a genuine regulatory history, a pivotal randomised trial behind its approvals, and a decades-long clinical record in dozens of countries. It also has, as of 2025, the single cleanest negative result in the whole peptide literature - a properly powered phase 3 trial that failed to confirm an earlier promising signal.

That combination makes it unusually useful to write about honestly. The interesting question is not whether thymosin alpha-1 "works". It is what it has been shown to do, in whom, and why none of that translates into availability or a sensible recommendation in the United States in 2026.

Two different molecules with a confusing shared name

Before anything else, a naming problem has to be cleared up, because in 2026 it stopped being merely pedantic and started producing wrong conclusions about what is and is not lawfully available.

"Thymosin" is not one substance. It was originally a name for a fraction extracted from thymic tissue, and that fraction contained multiple unrelated peptides. Two of them went on to separate careers, and they share almost nothing beyond the first word of their names.

Thymosin alpha-1 vs thymosin beta-4 (TB-500)

Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha. Its biology is immunological. It appears to act largely through Toll-like receptor signalling on dendritic cells, with downstream effects on T-cell maturation and function - in broad terms, it behaves as an immune modulator rather than an immune stimulant, nudging antigen-presenting cells and the T-cell compartment rather than driving a blunt increase in activity. It is the molecule with the drug approvals and the phase 3 trial - the thymosin alpha-1 compound reference covers the same molecule-level detail.

Thymosin beta-4, and its widely circulated fragment TB-500, is a different protein with a different job. Its biology centres on actin sequestration, cell migration and tissue repair, and the interest in it is orthopaedic and regenerative rather than immunological. It has no comparable approval record anywhere.

These are not variants of one another. They are not isoforms. They do not substitute for each other in any meaningful sense, and evidence about one carries no weight for the other. The shared prefix is a historical accident of how thymic extracts were named, and it is the origin of a great deal of confused reading - including, as the regulatory section below sets out, confusion about which molecule actually moved in 2026.

What thymosin alpha-1 does in the immune system

The mechanistic account is reasonably well characterised for a peptide of this class, which is itself unusual.

Thymosin alpha-1 engages pattern-recognition machinery - principally Toll-like receptors on dendritic cells - and through that engagement influences how those cells mature and how they present antigen. The downstream consequence is on T cells: effects on thymocyte differentiation, on the balance of T-helper subsets, and on the functional competence of T cells that are already circulating. Some work also describes effects on natural killer cell activity.

Two qualitative points are worth holding onto, because they shape what the compound plausibly could and could not do.

First, the effect is modulatory rather than unidirectional. Thymosin alpha-1 is not well described as "boosting immunity". The more defensible description is that it appears to shift immune signalling toward a more functional configuration in states where that configuration has been disturbed - which is why its clinical development has concentrated on chronic viral infection, sepsis and immune compromise in cancer patients rather than on healthy people.

Second, mechanism is not outcome. A peptide can have a well-mapped receptor interaction and a reproducible effect on cell-surface markers and still fail to change anything a patient would notice. That gap is precisely what the sepsis trial went looking for, and precisely what it did not find. The same logic applies across inflammatory biology generally, and it is why we keep returning to what an inflammatory marker actually measures rather than to mechanism stories.

Where it is an approved medicine, and for what

This is the part most coverage gets half-right, in a way that matters.

Approvals outside the US

Thymosin alpha-1 is marketed as Zadaxin and is approved in more than 35 countries. The principal approved indication is chronic hepatitis B. Some jurisdictions additionally cover hepatitis C, and some cover immune support in cancer patients - the exact scope varies by country, and the variation is not trivial.

So this is not a research chemical in the usual sense. It is a licensed pharmaceutical with a marketing authorisation, a manufacturer, pharmacovigilance obligations and a regulatory dossier, across a large part of the world.

Why "approved somewhere" is not "approved here"

It is also not approved in the United States, and the distance between those two facts is larger than it looks.

Approval is jurisdiction-specific by design. A regulator assesses a particular dossier, for a particular indication, against its own evidentiary standard and its own view of the therapeutic landscape it is approving into. A drug can clear one agency and not another because the evidence package was never submitted, because it was submitted and found insufficient, or because the comparator standard of care differs. None of those are interchangeable, and a citation of "approved in 35 countries" tells a US reader almost nothing about the third possibility.

For thymosin alpha-1 specifically, the landscape point is doing a lot of work. Its hepatitis B evidence was generated in an era whose standard of care has since been comprehensively replaced. A drug that looked reasonable against the alternatives available in the late 1990s is being asked to look reasonable against modern nucleos(t)ide antivirals, and that is a different and much harder question.

The practical consequence for anyone reading this from the US: an approval elsewhere does not create a lawful route to the compound here, does not import that jurisdiction's quality oversight, and does not make the compound's US status anything other than investigational.

The human evidence, ranked

The sepsis trial record

The strongest controlled evidence for thymosin alpha-1 is the TESTS trial, and it is a negative result.

TESTS was a multicentre, double-blind, randomised, placebo-controlled phase 3 study published in the BMJ in 2025. It enrolled 1,106 adults aged 18 to 85 with sepsis by Sepsis-3 criteria, randomised one-to-one - 552 to active treatment, 554 to placebo - across 22 centres in China, with enrolment running from September 2016 to December 2020.

The primary endpoint was 28-day all-cause mortality. The result: 23.4% in the thymosin alpha-1 arm versus 24.1% on placebo, hazard ratio 0.99 (95% CI 0.77 to 1.27), P=0.93. Ninety-day mortality followed the same pattern, hazard ratio 0.95 (0.77 to 1.17). No secondary outcome and no safety outcome differed significantly between arms. The authors' conclusion was that there is no clear evidence thymosin α1 reduces 28-day mortality in sepsis.

The context makes this more informative, not less. An earlier and smaller trial, ETASS, had been single-blind and considerably more encouraging, and it is the study that generated most of the enthusiasm for this indication. TESTS was larger, better blinded, and did not confirm it.

That sequence - a promising signal in a small, less rigorously blinded study, followed by a null result in a properly powered one - is worth naming clearly, because it is routinely misread as a scandal or a suppression. It is neither. It is the process working exactly as designed. Small early trials are noisy and their positive findings are, on base rates, more often wrong than right. The entire point of running a large, blinded, adequately powered confirmatory trial is to find out which early signals survive. Most do not. A field where every phase 2 signal confirmed in phase 3 would be a field that was not testing anything hard.

What TESTS establishes, then, is narrow and solid: in adults with sepsis, thymosin alpha-1 did not reduce mortality, and it did not appear to cause harm. It does not establish that the peptide is inert in every context. It does establish that the most-cited clinical hope for it has been tested and has not held.

The hepatitis B record

The evidence underpinning the approvals is older and much smaller.

The pivotal work is a 1998 randomised trial in 98 patients, which reported complete virological response in 40.6% of those receiving thymosin alpha-1 versus 9.4% of untreated controls. Taken at face value that is a substantial difference, and it is a real randomised comparison rather than an observational one.

It should still be read with its date attached. Ninety-eight patients is a small trial by any modern standard. It predates the current antiviral era entirely, and it used untreated controls rather than an active comparator - a design that answers "is this better than nothing" and not "is this better than what a patient would otherwise be given". Modern nucleos(t)ide analogues achieve viral suppression rates that were not on the table when this study was designed.

That is why the honest summary is: the hepatitis B evidence is sufficient to support approval in jurisdictions that granted it, and insufficient to make thymosin alpha-1 a current first-line option anywhere the modern agents are available. Both halves of that sentence are true simultaneously.

What has not been shown

Outside those two indications, the record thins out quickly. There is no adequately powered evidence that thymosin alpha-1 improves outcomes in healthy adults, that it usefully modifies chronic low-grade inflammation of the kind discussed under inflammaging, that it improves recovery, performance or longevity, or that it functions as a general immune-resilience intervention. Those are the uses most often discussed in consumer contexts, and they are the uses with the least behind them.

Nor is there evidence bearing on long-term administration in people who are not ill. Every meaningful trial has been conducted in a defined patient population with a defined disease. Extrapolating from a sepsis ICU or a hepatitis B clinic to a healthy adult seeking immune optimisation is not a small step, and nothing in the literature licenses it.

Its 2026 US regulatory position

Thymosin alpha-1 remains not FDA-approved in the United States. Nothing in 2026 changed that. But 2026 did change something adjacent, and the adjacency is where readers are going wrong.

In April 2026 the FDA removed twelve substances from its Category 2 list - the bucket for substances with significant safety concerns - effective late April 2026. Thymosin beta-4 (TB-500) was one of the twelve. Thymosin alpha-1 was not.

TB-500 then appeared on the docket of the Pharmacy Compounding Advisory Committee meeting of 23 to 24 July 2026, where it was among the six of seven substances the committee recommended for inclusion on the 503A bulks list. Thymosin alpha-1 was not on that docket at all. We covered the mechanics of that process in the 2026 FDA peptide reclassification and the outcomes in the vote results.

Five things about that chain need stating explicitly, because each one is routinely dropped.

PCAC recommendations are non-binding. The committee advises. It does not decide.

FDA's own scientists recommended against all seven substances. The committee voted the other way on six of them. That is a disagreement on the record, not a consensus.

Notice-and-comment rulemaking has not concluded. As of 13 September 2026 there is no final rule and no proposed rule arising from this process.

Removal from Category 2 is not promotion to Category 1. A substance removed from Category 2 sits in no category at all. It has not acquired eligibility; it has lost a specific negative designation.

Therefore nothing about lawful availability has changed - not for TB-500, and certainly not for thymosin alpha-1, which was never part of any of it.

The confusion runs into the regulatory record too

Here is why the naming problem earned its own section at the top of this page.

Until this year, conflating thymosin alpha-1 with thymosin beta-4 was an error of biology with limited practical consequence - the molecules were both unapproved in the US and both outside the compounding pathway. After April 2026 the two sit in genuinely different regulatory positions. One has been removed from a specific negative list and has been through an advisory vote. The other has not been touched.

So a reader who sees "thymosin removed from Category 2" and applies it to thymosin alpha-1 now draws a conclusion that is not merely imprecise but false. And the inverse error runs too: someone who reads a serious phase 3 trial of thymosin alpha-1 and takes it as evidence about TB-500's tissue-repair claims has imported a result from an unrelated molecule in an unrelated indication.

The right reading of that table is not that one molecule is ahead of the other. It is that they are on separate tracks, and that neither track has produced lawful US availability.

Who is asking about it, and why the answer is usually "not yet"

The people who ask us about thymosin alpha-1 are mostly not asking about sepsis or hepatitis B. They are asking because they get sick more often than they would like, or they are recovering from something that took longer than expected, or they have read that immune function declines with age and would like a lever on it.

Those are legitimate concerns, and the honest answer is that thymosin alpha-1 does not currently address them on any evidence we would be willing to cite.

The compound has been studied in people whose immune systems were under acute or chronic pathological stress. In the largest and most rigorous of those studies, it did not change the outcome that mattered. In the indication where it is approved, the supporting trial is small, nearly three decades old, and has been overtaken by better drugs. There is no body of work in healthy adults at all. And in the United States it is not an approved medicine, which means the question of what you would actually be getting is not answerable in any way we would be comfortable putting in writing.

What we would say instead is that the underlying complaint is usually worth characterising properly before reaching for a compound. Frequent infection, poor recovery and persistent low-grade inflammation have overlapping presentations and quite different causes, and the workup for them is unglamorous: sleep, glycaemic control, iron and vitamin D status, thyroid function, and an inflammatory marker read in context rather than in isolation. Some of the peptide literature adjacent to this space - LL-37 and the cathelicidin system, or the KPV fragment - is genuinely interesting biology, and the same evidentiary discipline applies to all of it. Where a compound's US status is in flux, the compounding position is a separate question from whether the compound works, and both have to clear before anything sensible can be said.

"Not yet" is not the same as "never". A larger, better-designed trial in a population where thymosin alpha-1 is plausibly doing something, reporting a clinical endpoint, would move this page. TESTS did not provide that. Nothing currently running looks likely to provide it soon.

Frequently asked questions

Is thymosin alpha-1 legal in the United States? It is not FDA-approved in the United States for any indication, which means it is investigational in this jurisdiction. Its approvals elsewhere - as Zadaxin, in more than 35 countries, principally for chronic hepatitis B - do not create a lawful US route, do not import that jurisdiction's oversight, and do not change its US status. Nothing in the 2026 FDA process touched thymosin alpha-1: it was not among the twelve substances removed from Category 2 in April 2026 and it was not on the July 2026 advisory committee docket.

Did the FDA approve thymosin alpha-1 in 2026? No. The 2026 activity concerned thymosin beta-4 (TB-500), a different molecule. TB-500 was removed from the Category 2 list and was subsequently recommended by an advisory committee for the 503A bulks list. Three qualifications apply even to that: the committee's recommendation is non-binding, FDA's own scientists recommended against it, and no proposed or final rule exists as of 13 September 2026. Removal from Category 2 also does not confer Category 1 eligibility - a removed substance sits in no category at all. Thymosin alpha-1 was not involved in any part of this.

Why did the sepsis trial fail if earlier studies were positive? Because the earlier study was smaller and single-blind, and the later one was larger, double-blind and adequately powered. The TESTS trial randomised 1,106 adults across 22 centres and found 28-day mortality of 23.4% on thymosin alpha-1 against 24.1% on placebo, with a hazard ratio of 0.99 and a P value of 0.93 - no signal at all, and no difference on any secondary or safety outcome. This is the ordinary and correct behaviour of a research process that is actually testing its hypotheses. Most early positive signals do not survive proper confirmation, which is why the confirmation is run.

Is thymosin alpha-1 worth considering for general immune support? On current evidence, no. Every meaningful trial has been conducted in patients with a defined disease - sepsis, chronic hepatitis B, immune compromise in cancer - and there is no body of controlled work in healthy adults, no long-term data outside disease populations, and no demonstrated effect on the outcomes people usually have in mind. Combined with its unapproved US status, that puts it well outside what we would discuss as an option. The more productive route is to characterise the underlying problem properly first.

---

Related reading

• The KPV peptide - anti-inflammatory fragment biology, and what its human record actually supports
• The 2026 FDA peptide reclassification - what the Category 2 removals did and did not do
• KPV, the FDA vote and access - how an advisory recommendation translates, and fails to translate, into availability
• Inflammaging - the chronic low-grade inflammation most immune questions are really about
• Peptides and autoimmune disease - why an immune-modulating peptide like thymosin alpha-1 needs a specialist conversation first when the immune system is already misdirected
• LL-37 (cathelicidin) - what it is, and why the FDA is reviewing it next

Part of Inflammation & Gut.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore Thymosin alpha-1.

Educational content, not medical advice. Thymosin alpha-1 is not FDA-approved in the United States and is investigational in that jurisdiction; approval in other countries does not confer US availability. No doses, protocols, sourcing or administration information appears anywhere on this page. Claims for the Malaysian market are subject to MAB requirements. Position stated as of 13 September 2026.

References

• Thymosin alpha-1: 28-amino-acid peptide derived from prothymosin alpha, originally isolated from thymic tissue; acts largely via Toll-like receptor signalling on dendritic cells with downstream effects on T-cell maturation and function.
• Zadaxin (thymosin alpha-1): approved in more than 35 countries, principally for chronic hepatitis B, with some approvals covering hepatitis C and immune support in cancer patients. Not FDA-approved in the United States.
• TESTS trial. Multicentre, double-blind, randomised, placebo-controlled phase 3 of thymosin α1 in sepsis. BMJ, 2025. 1,106 adults aged 18 to 85 meeting Sepsis-3 criteria; 1:1 randomisation (552 active / 554 placebo); 22 centres in China; enrolment September 2016 - December 2020. Primary outcome 28-day all-cause mortality: 23.4% active vs 24.1% placebo; HR 0.99 (95% CI 0.77 to 1.27); P=0.93. 90-day mortality HR 0.95 (0.77 to 1.17). No secondary or safety outcome differed significantly. Conclusion: no clear evidence that thymosin α1 reduces 28-day mortality in sepsis.
• ETASS. Earlier, smaller, single-blind randomised trial of thymosin α1 in sepsis reporting more encouraging results; not confirmed by the larger, better-blinded TESTS trial.
• Pivotal chronic hepatitis B trial, 1998. Randomised, 98 patients; complete virological response 40.6% with thymosin alpha-1 vs 9.4% in untreated controls. Small, predates the modern nucleos(t)ide antiviral era, and used untreated rather than active controls.
• FDA, April 2026: twelve substances removed from the Category 2 "significant safety concerns" list, effective late April 2026. Thymosin beta-4 (TB-500) was among them; thymosin alpha-1 was not.
• Pharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026: six of seven substances recommended for the 503A bulks list, including thymosin beta-4. Thymosin alpha-1 was not on the docket. PCAC recommendations are non-binding; FDA's own scientists recommended against all seven; notice-and-comment rulemaking has not concluded and as of 13 September 2026 there is no final rule and no proposed rule. Removal from Category 2 does not confer Category 1 eligibility - a removed substance sits in no category at all.